Product
KRAS vaccine
1 clinical trial
2 indications
Indication
Pancreatic Ductal AdenocarcinomaIndication
NSCLCClinical trial
A Phase 2 Study Evaluating the Efficacy of Anti-CD38 Antibody in Combination With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-01